European Respiratory Society guidelines for the diagnosis of asthma in adults
Publication date :
2022
Journal title :
European Respiratory Journal
ISSN :
0903-1936
eISSN :
1399-3003
Publisher :
European Respiratory Society
Volume :
60
Issue :
3
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
Conflict of interest: R. Louis reports grants and personal fees from GSK, AZ, Chiesi and Novartis, personal fees from Sanofi, outside the submitted work. I. Satia reports grants and personal fees from GSK and Merck, personal fees from AstraZeneca, grants from ERS Respire 3 Marie Curie Fellowship and E.J. Moran Campbell Early Career Award, outside the submitted work. I. Ojanguren reports grants and personal fees from AstraZeneca, Sanofi and GSK, personal fees and non-financial support from Boehringer Ingelheim and Chiesi, grants, personal fees and non-financial support from Novartis, personal fees from MSD, Puretech, Bial and TEVA, outside the submitted work. F. Schleich reports grants and personal fees for national board participation and presentations from GSK and AstraZeneca, personal fees for board participation and lectures from Chiesi, outside the submitted work. M. Bonini has nothing to disclose. T. Tonia reports acting as ERS Methodologist. D. Rigau worked as ERS methodologist until February 2020. A. ten Brinke reports institutional fees for research advisory board work from GSK, Sanofi, TEVA, AstraZeneca and Boehringer Ingelheim, institutional fees for lectures from AstraZeneca, GSK, TEVA and SanofiGenzyme, grants from AstraZeneca, GSK and TEVA, outside the submitted work. R. Buhl reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Novartis, Sanofi, Roche and Teva, and grants to Mainz University Hospital from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, all outside the submitted work. S. Loukides has nothing to disclose. J.W.H. Kocks reports grants, institutional fees and non-financial support from AstraZeneca and Boehringer Ingelheim, grants and institutional fees from Chiesi Pharmaceuticals, GSK, Novartis and TEVA, institutional fees from MSD and COVIS, outside the submitted work; and holds 72.5% of shares in the General Practitioners Research Institute. L-P. Boulet reports grants from Amgen, AstraZeneca, GlaxoSmithKline, Merck, Novartis and Sanofi-Regeneron, personal fees for consultancy and advisory board work from AstraZeneca, Novartis, GlaxoSmithKline, Merck and Sanofi-Regeneron, personal fees for lectures from AstraZeneca, Covis, GlaxoSmithKline, Novartis, Merck and Sanofi, grants and non-financial support from AstraZeneca, Covis, GlaxoSmithKline, Merck and Novartis, and is Chair of Global Initiative for Asthma (GINA) Board of Directors, President of the Global Asthma Organisation (Interasma) and Member of the Canadian Thoracic Society Respiratory Guidelines Committee. A. Bourdin reports grants, personal fees, non-financial support and other (investigator in clinical trials) from GSK, AstraZeneca, Boeringher Ingelheim and Actelion/Jansen, personal fees, non-financial support and other (investigator in clinical trials) from Novartis, Chiesi Farma, Sanofi Regeneron and Roche, non-financial support and other (investigator in clinical trials) from Teva, other (investigator in clinical trials) from United Therapeutics and Pulsar, outside the submitted work. C. Coleman is an employee of European Lung Foundation. K. Needham has nothing to disclose. M. Thomas reports personal fees from GSK, Boehringer Ingelheim and Chiesi, outside the submitted work. M. Idzko has nothing to disclose. A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and TEVA, board membership, consultancy, payment for lectures and travel expenses reimbursement from Mundipharma, Zambon, Novartis and Sanofi/Regeneron, grants for research, payment for lectures and travel expenses reimbursement from Menarini, board membership, consultancy and travel expenses reimbursement from Roche, grants from Fondazione Maugeri and Fondazione Chiesi, personal fees for consultancy from Edmondpharma, outside the submitted work. C. Porsbjerg reports grants and personal fees from Astra Zeneca, GSK, Novartis, TEVA, Sanofi and Chiesi, grants from Pharmaxis, outside the submitted work. D. Schuermans reports non-financial support from Free University of Brussels, outside the submitted work. J.B. Soriano has nothing to disclose. O.S. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, grants from Edmond Pharma, personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, Covis, Novartis, Mereo Biopharma, Orion, Menarini, Ucb, Trudell Medical, Deva and Kamada, outside the submitted work.
Bloom CI, Saglani S, Feary J, et al. Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016. Eur Respir J 2019; 53: 1802130.
Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-1259.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2021. Date last accessed: 31 May 2022. https://ginasthma.org
Aaron SD, Boulet LP, Reddel HK, et al. Underdiagnosis and overdiagnosis of asthma. Am J Respir Crit Care Med 2018; 198: 1012-1020.
Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365: 974-976.
Health Unlocked. 2020. Asthma Community Forum. https://healthunlocked.com/asthmalunguk-asthma/Date last accessed: 15 December 2021.
Health Unlocked. 2020. Is it really asthma? https://healthunlocked.com/asthmalunguk-asthma/posts/143924009/is-it-really-asthma/Date last accessed: 8 March 2022.
Health Unlocked. 2020. Lung function test and FeNO. https://healthunlocked.com/asthmalunguk-asthma/posts/144860286/lung-function-test-and-feno/Date last accessed: 8 March 2022.
Health Unlocked. 2020. Peak flow averages question. https://healthunlocked.com/asthmalunguk-asthma/posts/142437895/peak-flow-averages-question/Date last accessed: 8 March 2022.
Health Unlocked. 2020. New to asthma at 38…struggling. https://healthunlocked.com/asthmalungukasthma/posts/144948837/new-to-asthma-at-38...-struggling/Date last accessed: 8 March 2022.
National Institute for Health and Care Excellence. Asthma: Diagnosis, Monitoring and Chronic Asthma Management. NICE Guideline NG80. www.nice.org.uk/guidance/ng80/Date last updated: March 2021.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019; 200: e70-e88.
Pedrosa M, Cancelliere N, Barranco P, et al. Usefulness of exhaled nitric oxide for diagnosing asthma. J Asthma 2010; 47: 817-821.
Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 10: 4.
Garcia-Marcos L, Edwards J, Kennington E, et al. Priorities for future research into asthma diagnostic tools: a PAN-EU consensus exercise from the European asthma research innovation partnership (EARIP). Clin Exp Allergy 2018; 48: 104-120.
Akinbami LJ, Salo PM, Cloutier MM, et al. Primary care clinician adherence with asthma guidelines: the National Asthma Survey of Physicians. J Asthma 2020; 57: 543-555.
Lingner H, Burger B, Kardos P, et al. What patients really think about asthma guidelines: barriers to guideline implementation from the patients' perspective. BMC Pulm Med 2017; 17: 13.
Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-1110.
Miravitlles M, Tonia T, Rigau D, et al. New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards. Eur Respir J 2018; 51: 1800221.
Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725.
Brożek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66: 588-595.
Johnson B, Steenbruggen I, Graham BL, et al. Improving spirometry testing by understanding patient preferences. ERJ Open Res 2021; 7: 00712-2020.
Asthma: Being Diagnosed with Asthma. www.healthtalk.org/asthma/being-diagnosed-with-asthma/Date last updated: August 2017.
Asthma: Adult Onset of Asthma. www.healthtalk.org/asthma/adult-onset-of-asthma/Date last updated: August 2017.
Asthma: Dealing with Health Professionals. www.healthtalk.org/asthma/dealing-with-health-professionals/Date last updated: August 2017.
Asthma: Emotions and Coping with Asthma. www.healthtalk.org/asthma/emotions-and-coping-with-asthma/Date last updated: August 2017.
Bougard N, Nekoee H, Schleich F, et al. Assessment of diagnostic accuracy of lung function indices and FeNO for a positive methacholine challenge. Biochem Pharmacol 2020; 179: 113981.
Hunter CJ, Brightling CE, Woltmann G, et al. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121: 1051-1057.
Nekoee H, Graulich E, Schleich F, et al. Are type-2 biomarkers of any help in asthma diagnosis? ERJ Open Res 2020; 6: 00169-2020.
Stanbrook MB, Chapman KR, Kesten S. Gas trapping as a predictor of positive methacholine challenge in patients with normal spirometry results. Chest 1995; 107: 992-995.
Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63: 1046-1051.
Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-369.
den Otter JJ, Reijnen GM, van den Bosch WJ, et al. Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability? Br J Gen Pract 1997; 47: 487-492.
Goldstein MF, Veza BA, Dunsky EH, et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV1 responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119: 1001-1010.
Parameswaran K, Belda J, Sears MR. Use of peak flow variability and methacholine responsiveness in predicting changes from pre-test diagnosis of asthma. Eur Respir J 1999; 14: 1358-1362.
Thiadens HA, de Bock GH, Dekker FW, et al. Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study. BMJ 1998; 316: 1286-1290.
Ulrik CS, Postma DS, Backer V. Recognition of asthma in adolescents and young adults: which objective measure is best? J Asthma 2005; 42: 549-554.
Drake S, Wang R, Healy L, et al. Diagnosing asthma with and without aerosol-generating procedures. J Allergy Clin Immunol Pract 2021; 9: 4243-4251.
Dean BW, Birnie EE, Whitmore GA, et al. Between-visit variability in FEV1 as a diagnostic test for asthma in adults. Ann Am Thorac Soc 2018; 15: 1039-1046.
American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol 2016; 138: 1296-1298.
Haccuria A, Michils A, Michiels S, et al. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. J Allergy Clin Immunol 2014; 134: 554-559.
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-615.
Pavord ID, Siddiqui S, Papi A, et al. Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function. J Asthma Allergy 2020; 13: 701-711.
Arora R, Thornblade CE, Dauby PA, et al. Exhaled nitric oxide levels in military recruits with new onset asthma. Allergy Asthma Proc 2006; 27: 493-498.
Cirillo I, Ricciardolo FL, Medusei G, et al. Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy Immunol 2013; 160: 322-328.
Cordeiro D, Rudolphus A, Snoey E, et al. Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy Asthma Proc 2011; 32: 119-126.
Fortuna AM, Feixas T, González M, et al. Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count. Respir Med 2007; 101: 2416-2421.
Fukuhara A, Saito J, Sato S, et al. Validation study of asthma screening criteria based on subjective symptoms and fractional exhaled nitric oxide. Ann Allergy Asthma Immunol 2011; 107: 480-486.
He L, Wei M, Luo J, et al. Re-evaluation of the diagnostic value of fractional exhaled nitric oxide & its impact in patients with asthma. Indian J Med Res 2018; 148: 441-448.
Heffler E, Guida G, Marsico P, et al. Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms. Respir Med 2006; 100: 1981-1987.
Kaplan AG. Chronic cough in adults: make the diagnosis and make a difference. Pulm Ther 2019; 5: 11-21.
Karrasch S, Linde K, Rücker G, et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax 2017; 72: 109-116.
Katsoulis K, Ganavias L, Michailopoulos P, et al. Exhaled nitric oxide as screening tool in subjects with suspected asthma without reversibility. Int Arch Allergy Immunol 2013; 162: 58-64.
Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 290-300.
Kostikas K, Papaioannou AI, Tanou K, et al. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest 2008; 133: 906-913.
Kowal K, Bodzenta-Lukaszyk A, Zukowski S. Exhaled nitric oxide in evaluation of young adults with chronic cough. J Asthma 2009; 46: 692-698.
Malinovschi A, Backer V, Harving H, et al. The value of exhaled nitric oxide to identify asthma in smoking patients with asthma-like symptoms. Respir Med 2012; 106: 794-801.
Martin MJ, Wilson E, Gerrard-Tarpey W, et al. The utility of exhaled nitric oxide in patients with suspected asthma. Thorax 2016; 71: 562-564.
Schleich FN, Asandei R, Manise M, et al. Is FENO50 useful diagnostic tool in suspected asthma? Int J Clin Pract 2012; 66: 158-165.
Schneider A, Schwarzbach J, Faderl B, et al. FENO measurement and sputum analysis for diagnosing asthma in clinical practice. Respir Med 2013; 107: 209-216.
Tilemann L, Gindner L, Meyer F, et al. Differences in local and systemic inflammatory markers in patients with obstructive airways disease. Prim Care Respir J 2011; 20: 407-414.
Wang Y, Li L, Han R, et al. Diagnostic value and influencing factors of fractional exhaled nitric oxide in suspected asthma patients. Int J Clin Exp Pathol 2015; 8: 5570-5576.
Berkman N, Avital A, Breuer R, et al. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60: 383-388.
Dupont LJ, Rochette F, Demedts MG, et al. Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma. Am J Respir Crit Care Med 1998; 157: 894-898.
Ojanguren I, Plaza V. FeNO for asthma diagnosis in adults: more lights than shadows. Arch Bronconeumol 2021; 57: 85-86.
Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol 2019; 144: 1-12.
Nakagome K, Nagata M. Involvement and possible role of eosinophils in asthma exacerbation. Front Immunol 2018; 9: 2220.
Popović-Grle S, Mehulić M, Pavicić F, et al. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung function in the diagnosis of asthma in persons with dyspnea. Coll Antropol 2002; 26: Suppl, 119-127.
Yurdakul AS, Dursun B, Canbakan S, et al. The assessment of validity of different asthma diagnostic tools in adults. J Asthma 2005; 42: 843-846.
Howarth PH. The airway inflammatory response in allergic asthma and its relationship to clinical disease. Allergy 1995; 50: Suppl 22, 13-21.
Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153: 1931-1937.
Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009; 39: 1145-1151.
Sunyer J, Antó JM, Castellsagué J, et al. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. Eur Respir J 1996; 9: 1880-1884.
Jarvis D, Luczynska C, Chinn S, et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. J Allergy Clin Immunol 2005; 116: 675-682.
Kerkhof M, Droste JH, de Monchy JG, et al. Distribution of total serum IgE and specific IgE to common aeroallergens by sex and age, and their relationship to each other in a random sample of the Dutch general population aged 20-70 years. Dutch ECRHS Group, European Community Respiratory Health Study. Allergy 1996; 51: 770-776.
Manise M, Bakayoko B, Schleich F, et al. IgE mediated sensitisation to aeroallergens in an asthmatic cohort: relationship with inflammatory phenotypes and disease severity. Int J Clin Pract 2016; 70: 596-605.
Haughney J, Morice A, Blyth KG, et al. A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med 2018; 134: 117-123.
Gerday S, Schleich F, Henket M, et al. Asthmatics with concordant eosinophilic disease classified according to their serum IgE status. Respir Med Res 2021; 79: 100797.
Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing - 1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: 309-329.
Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J 2003; 21: 1050-1068.
Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49: 1601526.
Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J 2018; 52: 1801033.
Porpodis K, Domvri K, Kontakiotis T, et al. Comparison of diagnostic validity of mannitol and methacholine challenges and relationship to clinical status and airway inflammation in steroid-naive asthmatic patients. J Asthma 2017; 54: 520-529.
Louis R, Bougard N, Guissard F, et al. Bronchodilation test with inhaled salbutamol versus bronchial methacholine challenge to make an asthma diagnosis: do they provide the same information? J Allergy Clin Immunol Pract 2020; 8: 618-625.
Topalovic M, Derom E, Osadnik CR, et al. Airways resistance and specific conductance for the diagnosis of obstructive airways diseases. Respir Res 2015; 16: 88.
Perez T, Chanez P, Dusser D, et al. Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. Respir Med 2013; 107: 1667-1674.
Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 2019; 7: 402-416.
Boulet LP, Turcotte H, Prince P, et al. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Respir Med 2009; 103: 1554-1563.
Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-836.
Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317: 269-279.
Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372: 1049-1057.
Kocks JWH, Andringa HJH, van Heijst E, et al. Aeroallergen sensitization for detecting asthma in primary care: a diagnostic test accuracy study. Clin Exp Allergy 2021; 51: 1080-1084.
Amelink M, de Nijs SB, Berger M, et al. Non-atopic males with adult onset asthma are at risk of persistent airflow limitation. Clin Exp Allergy 2012; 42: 769-774.
de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016; 2: 00100-2015.
Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-833.
Graff S, Bricmont N, Moermans C, et al. Clinical and biological factors associated with irreversible airway obstruction in adult asthma. Respir Med 2020; 175: 106202.
van Huisstede A, Castro Cabezas M, van de Geijn GJ, et al. Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med 2013; 107: 1356-1364.
Halvorsen T, Walsted ES, Bucca C, et al. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement. Eur Respir J 2017; 50: 1602221.
Balkissoon R, Kenn K. Asthma: vocal cord dysfunction (VCD) and other dysfunctional breathing disorders. Semin Respir Crit Care Med 2012; 33: 595-605.
Walsted ES, Famokunwa B, Andersen L, et al. Characteristics and impact of exercise-induced laryngeal obstruction: an international perspective. ERJ Open Res 2021; 7: 00195-2021.
Bommart S, Marin G, Molinari N, et al. Club cell secretory protein serum concentration is a surrogate marker of small-airway involvement in asthmatic patients. J Allergy Clin Immunol 2017; 140: 581-584.
Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012; 83: 520-528.
Tunon-de-Lara JM, Laurent F, Giraud V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007; 119: 583-590.
Venegas JG, Winkler T, Musch G, et al. Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature 2005; 434: 777-782.
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
Bakakos P, Schleich F, Alchanatis M, et al. Induced sputum in asthma: from bench to bedside. Curr Med Chem 2011; 18: 1415-1422.
Hargreave FE. The investigation of airway inflammation in asthma: sputum examination. Clin Exp Allergy 1997; 27: Suppl. 1, 36-40.
Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 125: 1028-1036.
Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723-1732.
Ntontsi P, Loukides S, Bakakos P, et al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes. Allergy 2017; 72: 1761-1767.
Demarche S, Schleich F, Henket M, et al. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med 2016; 16: 46.
Louis RE, Schleich FN. Granulocytic airway inflammation and clinical asthma outcomes. Am J Respir Crit Care Med 2021; 203: 797-799.
Hastie AT, Mauger DT, Denlinger LC, et al. Mixed sputum granulocyte longitudinal impact on lung function in the severe asthma research program. Am J Respir Crit Care Med 2021; 203: 882-892.
Pavord ID, Holliday M, Reddel HK, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med 2020; 8: 671-680.
Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med 2018; 6: 29-39.
Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172: 453-459.
da Silva J, Hilzendeger C, Moermans C, et al. Raised interferon-β, type 3 interferon and interferon-stimulated genes - evidence of innate immune activation in neutrophilic asthma. Clin Exp Allergy 2017; 47: 313-323.
Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211-218.
Abdel-Aziz MI, Brinkman P, Vijverberg SJH, et al. Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. J Allergy Clin Immunol 2021; 147: 123-134.
Azim A, Green B, Lau L, et al. Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma. Allergy 2021; 76: 2070-2078.
Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
Schleich FN, Zanella D, Stefanuto PH, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019; 200: 444-453.
Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350-400.
Louis R, Roche N. Personalised medicine: are we ready? Eur Respir Rev 2017; 26: 170088.
Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
McDonald VM, Clark VL, Cordova-Rivera L, et al. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J 2020; 55: 1901509.
Agustí A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J 2017; 50: 1701655.
Hannane A, Misane L, Devouassoux G, et al. Asthma patients' perception on their care pathway: a qualitative study. NPJ Prim Care Respir Med 2019; 29: 9.
Gater A, Nelsen L, Fleming S, et al. Assessing asthma symptoms in adolescents and adults: qualitative research supporting development of the asthma daily symptom diary. Value Health 2016; 19: 440-450.
Duong M, Islam S, Rangarajan S, et al. Global differences in lung function by region (PURE): an international, community-based prospective study. Lancet Respir Med 2013; 1: 599-609.
Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691-706.
Gross NJ. What is this thing called love? - or, defining asthma. Am Rev Respir Dis 1980; 121: 203-204.